Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Beta Bionics, Inc. Common Stock (BBNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BBNX (1-star) is a SELL. SELL since 3 days. Profits (-0.73%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $
1 Year Target Price $
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.73% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 945.12M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 8.89 - 24.50 | Updated Date 06/22/2025 |
52 Weeks Range 8.89 - 24.50 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -104.64% | Operating Margin (TTM) -65.71% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 891525977 | Price to Sales(TTM) 17.82 |
Enterprise Value 891525977 | Price to Sales(TTM) 17.82 | ||
Enterprise Value to Revenue 16.81 | Enterprise Value to EBITDA - | Shares Outstanding 43334300 | Shares Floating 41336549 |
Shares Outstanding 43334300 | Shares Floating 41336549 | ||
Percent Insiders 6.74 | Percent Institutions 55.22 |
Analyst Ratings
Rating 4.29 | Target Price - | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Beta Bionics, Inc. Common Stock
Company Overview
History and Background
Beta Bionics, Inc. is a private company focused on developing and commercializing advanced diabetes management technologies, particularly the iLet Bionic Pancreas. Founded in 2015, it spun out of Boston University and is based in Concord, Massachusetts. The company's mission is to revolutionize diabetes care through automation and personalized medicine.
Core Business Areas
- Diabetes Management: Development and commercialization of the iLet Bionic Pancreas, an automated insulin delivery system.
Leadership and Structure
Sean Saint is the Chief Executive Officer. The company has a board of directors that includes representatives from venture capital firms and healthcare experts. Beta Bionics operates with a functional structure organized around product development, clinical research, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- iLet Bionic Pancreas: The iLet Bionic Pancreas is an automated insulin delivery system that uses an algorithm to determine and administer insulin doses based on continuous glucose monitoring data. Competitors include Medtronic (MDT), Tandem Diabetes Care (TNDM), and Insulet (PODD). Market share data is difficult to ascertain due to Beta Bionics being privately held, and the product being recently launched. Market share is estimated in the US at under 5% currently but with growth potential.
Market Dynamics
Industry Overview
The diabetes management market is experiencing substantial growth, driven by the increasing prevalence of diabetes globally and advancements in technology, such as continuous glucose monitors and automated insulin delivery systems. The market is competitive, with established players and emerging companies vying for market share.
Positioning
Beta Bionics is positioned as an innovator in the diabetes technology space, specifically focused on automated insulin delivery. The iLet system represents a next-generation approach to diabetes management, aiming to simplify and personalize treatment.
Total Addressable Market (TAM)
The global diabetes care devices market is estimated at approximately $30 billion. Beta Bionics is positioned to capture a portion of this TAM through its iLet Bionic Pancreas, particularly among individuals with type 1 diabetes and those seeking more automated and personalized treatment options.
Upturn SWOT Analysis
Strengths
- Innovative technology (iLet Bionic Pancreas)
- Strong clinical data supporting product efficacy
- Focus on automated and personalized diabetes management
- Experienced leadership team
Weaknesses
- Limited commercial presence compared to larger competitors
- Reliance on single product (iLet)
- High manufacturing costs associated with advanced technology
- Private company limits access to capital
Opportunities
- Expanding market for diabetes management technologies
- Partnerships with healthcare providers and payers
- Geographic expansion into international markets
- Development of next-generation diabetes management solutions
Threats
- Competition from established players (Medtronic, Tandem, Insulet)
- Regulatory hurdles and approval timelines
- Reimbursement challenges from payers
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- MDT
- TNDM
- PODD
Competitive Landscape
Beta Bionics differentiates itself through its focus on automation and personalized medicine. Its iLet system aims to simplify diabetes management compared to existing solutions. However, it faces competition from larger companies with established market presence and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's private status. Growth is expected to accelerate with the commercial launch of the iLet Bionic Pancreas.
Future Projections: Future growth projections are positive, driven by increasing adoption of automated insulin delivery systems and the potential for expanded indications and geographic reach.
Recent Initiatives: Recent initiatives include securing FDA approval for the iLet Bionic Pancreas, expanding manufacturing capacity, and building a commercial sales and marketing team.
Summary
Beta Bionics is a promising company in the diabetes management space, with innovative technology offering automated insulin delivery. Their challenge lies in penetrating a market dominated by larger, established players. The iLet's commercial success will hinge on effective marketing, distribution, and securing favorable reimbursement policies. Competition is intense, and ongoing innovation is vital for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Market analysis
- Press releases
- SEC Filings of Competitors
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Data on Beta Bionics is limited due to its private status. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beta Bionics, Inc. Common Stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2025-01-30 | President, CEO & Director Mr. Sean T. Saint PE | ||
Sector Healthcare | Industry Medical Devices | Full time employees 352 | Website https://www.betabionics.com |
Full time employees 352 | Website https://www.betabionics.com | ||
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.